Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 28 | 2021 | 42 | 8.330 |
Why?
|
| Antiviral Agents | 30 | 2021 | 66 | 6.960 |
Why?
|
| Hepatitis C | 19 | 2022 | 42 | 6.180 |
Why?
|
| Liver Diseases | 13 | 2022 | 33 | 4.960 |
Why?
|
| Hepacivirus | 23 | 2022 | 32 | 4.390 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 47 | 3.690 |
Why?
|
| Liver Transplantation | 9 | 2023 | 81 | 3.640 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.030 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 21 | 1.770 |
Why?
|
| Pregnancy | 13 | 2022 | 324 | 1.640 |
Why?
|
| Liver Cirrhosis | 12 | 2024 | 40 | 1.620 |
Why?
|
| Humans | 66 | 2024 | 22947 | 1.600 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 9 | 1.430 |
Why?
|
| Ribavirin | 8 | 2016 | 9 | 1.290 |
Why?
|
| Coinfection | 4 | 2023 | 20 | 1.220 |
Why?
|
| Sulfonamides | 7 | 2020 | 45 | 1.150 |
Why?
|
| HIV Infections | 4 | 2021 | 431 | 1.140 |
Why?
|
| Hepatitis B | 5 | 2019 | 12 | 1.130 |
Why?
|
| Female | 35 | 2024 | 12954 | 1.090 |
Why?
|
| United States | 18 | 2022 | 1765 | 1.040 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 4 | 0.990 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 103 | 0.930 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.900 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 24 | 0.880 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.840 |
Why?
|
| Interferon-alpha | 4 | 2012 | 30 | 0.840 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 36 | 0.830 |
Why?
|
| Treatment Outcome | 19 | 2021 | 2941 | 0.820 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.810 |
Why?
|
| Drug Therapy, Combination | 12 | 2021 | 162 | 0.750 |
Why?
|
| Gastroenterology | 3 | 2017 | 9 | 0.740 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 31 | 0.730 |
Why?
|
| Living Donors | 1 | 2021 | 16 | 0.700 |
Why?
|
| Prejudice | 1 | 2021 | 30 | 0.700 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 97 | 0.660 |
Why?
|
| Patient Selection | 1 | 2021 | 167 | 0.660 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 21 | 0.660 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 32 | 0.650 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 21 | 0.650 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.640 |
Why?
|
| Genotype | 10 | 2017 | 248 | 0.640 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 113 | 0.640 |
Why?
|
| Algorithms | 2 | 2020 | 304 | 0.600 |
Why?
|
| Adult | 19 | 2021 | 6923 | 0.600 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.600 |
Why?
|
| Viral Load | 5 | 2016 | 70 | 0.600 |
Why?
|
| Obesity | 1 | 2021 | 289 | 0.580 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.580 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.580 |
Why?
|
| Fear | 1 | 2018 | 45 | 0.560 |
Why?
|
| Liver | 3 | 2022 | 137 | 0.550 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.550 |
Why?
|
| Middle Aged | 19 | 2021 | 7910 | 0.520 |
Why?
|
| Cyclopropanes | 5 | 2020 | 13 | 0.500 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.500 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.490 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 11 | 0.490 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 3 | 0.490 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.490 |
Why?
|
| Virology | 1 | 2015 | 1 | 0.480 |
Why?
|
| Young Adult | 9 | 2021 | 1651 | 0.470 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 311 | 0.450 |
Why?
|
| Length of Stay | 2 | 2016 | 298 | 0.440 |
Why?
|
| Patient Readmission | 1 | 2016 | 117 | 0.440 |
Why?
|
| Liver Function Tests | 3 | 2022 | 21 | 0.440 |
Why?
|
| Risk Factors | 6 | 2023 | 1970 | 0.430 |
Why?
|
| Heart Failure | 1 | 2016 | 141 | 0.430 |
Why?
|
| Male | 21 | 2021 | 12458 | 0.420 |
Why?
|
| Prevalence | 3 | 2023 | 375 | 0.420 |
Why?
|
| Prognosis | 5 | 2022 | 730 | 0.410 |
Why?
|
| Preventive Health Services | 1 | 2013 | 10 | 0.400 |
Why?
|
| Advisory Committees | 1 | 2013 | 15 | 0.400 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 31 | 0.400 |
Why?
|
| Health Policy | 1 | 2013 | 28 | 0.400 |
Why?
|
| Retrospective Studies | 8 | 2024 | 2994 | 0.390 |
Why?
|
| Mass Screening | 4 | 2021 | 161 | 0.390 |
Why?
|
| Disease Management | 2 | 2016 | 100 | 0.380 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.360 |
Why?
|
| Proline | 4 | 2019 | 10 | 0.340 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 5 | 0.340 |
Why?
|
| Imidazoles | 4 | 2020 | 62 | 0.330 |
Why?
|
| RNA, Viral | 4 | 2022 | 44 | 0.330 |
Why?
|
| Aged | 13 | 2020 | 7447 | 0.320 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.320 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 19 | 0.320 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 13 | 0.320 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 153 | 0.290 |
Why?
|
| Cost of Illness | 2 | 2023 | 43 | 0.280 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 2 | 0.280 |
Why?
|
| Motivation | 3 | 2023 | 82 | 0.280 |
Why?
|
| Cohort Studies | 5 | 2021 | 1417 | 0.270 |
Why?
|
| Fatty Liver | 2 | 2019 | 26 | 0.270 |
Why?
|
| Medication Adherence | 2 | 2019 | 49 | 0.260 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 164 | 0.260 |
Why?
|
| Adolescent | 4 | 2020 | 1881 | 0.250 |
Why?
|
| Societies, Medical | 2 | 2017 | 117 | 0.240 |
Why?
|
| Benzofurans | 3 | 2020 | 5 | 0.240 |
Why?
|
| Graft Rejection | 2 | 2018 | 64 | 0.230 |
Why?
|
| Valine | 4 | 2019 | 4 | 0.220 |
Why?
|
| Incidence | 2 | 2020 | 624 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 107 | 0.210 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.210 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.200 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.200 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 5 | 0.200 |
Why?
|
| Amides | 2 | 2020 | 15 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2020 | 375 | 0.200 |
Why?
|
| Benzamides | 1 | 2023 | 12 | 0.200 |
Why?
|
| Vaccination | 1 | 2023 | 26 | 0.200 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.190 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2018 | 548 | 0.190 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 6 | 0.190 |
Why?
|
| RNA | 1 | 2022 | 30 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 3728 | 0.190 |
Why?
|
| Fibrosis | 1 | 2022 | 30 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 6 | 0.180 |
Why?
|
| Graft Survival | 2 | 2019 | 84 | 0.180 |
Why?
|
| Fertility | 1 | 2021 | 17 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 97 | 0.180 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.180 |
Why?
|
| Leucine | 2 | 2018 | 11 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 65 | 0.170 |
Why?
|
| World Health Organization | 1 | 2020 | 8 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 206 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2019 | 1493 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 10 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 268 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 134 | 0.160 |
Why?
|
| Anilides | 2 | 2019 | 5 | 0.160 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2020 | 74 | 0.160 |
Why?
|
| Consensus | 2 | 2021 | 81 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 78 | 0.150 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 235 | 0.150 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 18 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2019 | 51 | 0.150 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 17 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2018 | 21 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 537 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 315 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 801 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2017 | 19 | 0.130 |
Why?
|
| Psychometrics | 1 | 2018 | 176 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1020 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 43 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 286 | 0.130 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 5 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 9 | 0.120 |
Why?
|
| Safety | 1 | 2016 | 34 | 0.120 |
Why?
|
| Canada | 1 | 2016 | 42 | 0.120 |
Why?
|
| Quality Control | 1 | 2016 | 25 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 2 | 0.120 |
Why?
|
| Fraud | 1 | 2016 | 16 | 0.120 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Interferons | 1 | 2016 | 9 | 0.120 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.120 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 7 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 125 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 19 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 121 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 35 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 10 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 28 | 0.120 |
Why?
|
| Time Factors | 2 | 2016 | 1262 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 97 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 3 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 12 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 126 | 0.110 |
Why?
|
| Indoles | 1 | 2015 | 32 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 243 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 260 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 2 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 48 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 61 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2016 | 198 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 93 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 4 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.090 |
Why?
|
| Drug Combinations | 3 | 2017 | 31 | 0.090 |
Why?
|
| Comorbidity | 3 | 2018 | 426 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 94 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 5 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 17 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 112 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 113 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1412 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 219 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 286 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 351 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 442 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 190 | 0.070 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 760 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 57 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 21 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 57 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 14 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 168 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 30 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 17 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 173 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2017 | 69 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 18 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 39 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 41 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 134 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 6 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 23 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 28 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 126 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 29 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 30 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 592 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 439 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 110 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 125 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 129 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 309 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 190 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 3 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 55 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 42 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 113 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 33 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 33 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 71 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 113 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 811 | 0.020 |
Why?
|